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Abstract: Iron supplementation may have adverse health effects in infants, probably through
manipulation of the gut microbiome. Previous research in low-resource settings have focused
primarily on anemic infants. This was a double blind, randomized, controlled trial of home
fortification comparing multiple micronutrient powder (MNP) with and without iron. Six-month-old,
non- or mildly anemic, predominantly-breastfed Kenyan infants in a rural malaria-endemic area were
randomized to consume: (1) MNP containing 12.5 mg iron (MNP+Fe, n = 13); (2) MNP containing no
iron (MNP−Fe, n = 13); or (3) Placebo (CONTROL, n = 7), from 6–9 months of age. Fecal microbiota
were profiled by high-throughput bacterial 16S rRNA gene sequencing. Markers of inflammation
in serum and stool samples were also measured. At baseline, the most abundant phylum was
Proteobacteria (37.6% of rRNA sequences). The proteobacterial genus Escherichia was the most
abundant genus across all phyla (30.1% of sequences). At the end of the intervention, the relative
abundance of Escherichia significantly decreased in MNP−Fe (−16.05± 6.9%, p = 0.05) and CONTROL
(−19.75 ± 4.5%, p = 0.01), but not in the MNP+Fe group (−6.23 ± 9%, p = 0.41). The second most
abundant genus at baseline was Bifidobacterium (17.3%), the relative abundance of which significantly
decreased in MNP+Fe (−6.38 ± 2.5%, p = 0.02) and CONTROL (−8.05 ± 1.46%, p = 0.01), but not
in MNP-Fe (−4.27 ± 5%, p = 0.4445). Clostridium increased in MNP-Fe only (1.9 ± 0.5%, p = 0.02).
No significant differences were observed in inflammation markers, except for IL-8, which decreased
in CONTROL. MNP fortification over three months in non- or mildly anemic Kenyan infants can
potentially alter the gut microbiome. Consistent with previous research, addition of iron to the MNP
may adversely affect the colonization of potential beneficial microbes and attenuate the decrease of
potential pathogens.
Keywords: infants; iron; microbiome; multiple micronutrient powder
1. Introduction
Iron deficiency (ID) and iron deficiency anemia (IDA) are among the most prevalent micronutrient
deficiencies in the world [1]. Iron fortification in the form of oral micronutrient powders (MNP) is a
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common corrective strategy to prevent ID, IDA, or other micronutrient-related deficiencies, especially
in low-resource settings [1,2]. However, iron supplementation has been associated with increased
occurrence of adverse events, such as infectious diseases and inflammation, which may lead to
increased mortality, especially in malaria-endemic areas. For example, the trial conducted in Pemba,
Zanzibar [3] found that iron supplementation (12.5 mg/day) was associated with more death and
hospitalization in infants and young children compared with the placebo group. Moreover, a recent
trial in Pakistan also showed that MNP+Fe resulted in an increased proportion of days with diarrhea
and increased incidence of bloody diarrhea in older infants and toddlers [4].
Although iron is an essential micronutrient for infant growth and neurodevelopment, it is also an
indispensable nutrient for many pathogenic bacteria in the gut, including Salmonella spp., Shigella spp.,
and pathogenic E. coli [5]. Unabsorbed iron in the gut, usually caused by excessive iron intake (by
fortification or supplementation), fosters growth of these pathogenic strains [6] and could potentially
modify the balance of microbial species inhabiting the gut, and may thereby pose long-term health
consequences. However, research assessing the gut microbiome in relation to iron supplementation
in infants is quite limited. An earlier study [7] conducted in young infants (0–3 months) found that
infants consuming iron-fortified cow’s milk (5 mg/L) had lower counts of bifidobacteria and higher
counts of Escherichia coli, compared with infants consuming non-fortified cow’s milk or breastmilk.
Bifidobacteria are common probiotics and strongly sequester iron. Certain high iron-binding strains
of bifidobacteria inhibit the growth of iron-dependent pathogens, including Salmonella typhimurium
(S. typhi) and Escherichia coli O157:H45 [8]. Our research group conducted a controlled feeding study
in older U.S. breastfed infants and found a greater decrease of the genus Bifidobacterium over time in
infants consuming iron-fortified cereal from 5–9 months of age [9]. This alteration of the gut microbiota
in favor of less beneficial and more potentially pathogenic strains, could directly affect the host’s health
status. Indeed, a six-month, double-blind, randomized, controlled trial in Cote d’Ivoire reported that
iron fortification (20 mg/day) not only led to an unfavorable gut microbiome profile, but also increased
gut inflammation in anemic African children (6–14 years old) [10]. Furthermore, a recent trial by
Jaeggi et al. in primarily anemic Kenyan infants [11] receiving 12.5 or 2.5 mg/day of iron in the form of
MNP found that iron supplementation increased Escherichia/Shigella and Clostridium accompanied by
elevated intestinal inflammation status. These studies, although limited and heterogeneous in design,
location and age group, suggest the urgent need to further evaluate the effects of iron supplementation
on the gut microbiome, especially during infancy when early microbiota colonization is taking place
and in non-anemic infants who may not need iron supplementation and are, thus, more susceptible to
the potential adverse effects of iron.
The main objective of this study was to assess the effects of iron fortification in the form of MNP
on the gut microbiome and inflammation status in six-month-old, non- or mildly-anemic Kenyan
infants. Our primary hypothesis was that iron supplementation would increase the abundance of
pathogenic bacteria and decrease the abundance of beneficial bacteria over a three-month intervention.
Systemic and intestinal inflammation markers were hypothesized to also increase over time.
2. Materials and Methods
2.1. Study Design
This study was conducted in rural Kenya, approximately 150 km from Eldoret. Among the villages
where subjects were recruited, the majority of the population lived below the World Bank-defined
poverty level, and the prevalence of malaria is considered to be endemic. Details of the environment
were published previously [2]. Study subjects were recruited from the birth registry of the Global
Network for Women’s and Children’s Health [12]. The registry administrators provided a list of
45 consecutive infants at this age from their registers based on the study inclusion criteria (see below).
For the purpose of identifying participants, the study field staff and the registry administrator visited
each infant’s home before enrollment [2].
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This was a double-blind, individually-randomized, controlled trial with two primary aims: (1) To
identify the effects of iron on the gut microbiome and inflammation status of the host in non- or
mildly-anemic infants; and (2) To determine the effects of iron in MNP on zinc absorption and the size
of the exchangeable zinc pool, as an indicator of zinc status, after three months of home fortification
with daily MNP in maize-based diets [2]. In brief, subjects (15 per group) were randomized to one of
the three MNP groups: (1) The MNP+Fe group: MNP with iron (12.5 mg/day) and zinc (5 mg/day);
(2) The MNP-Fe group: the same MNP, except no iron; (3) the CONTROL group: placebo with
no micronutrients. The intervention started at 6 months of age and ended at nine months of age.
This study was approved by the Colorado Multiple Institutional Review Board and Moi University
Institutional Review Board. Potential families were visited and educated on the proposed study before
the enrollment visit and the study nurse or lab technologist obtained written informed consent from
the parents/guardians plus witness upon confirmation that the child met the inclusion and exclusion
criteria. Forty-five pieces of paper with letters marked A, B, or C to represent the three study arms
were rolled into balls and placed in a plastic container. The pieces were mixed thoroughly through
shaking of the container. An independent person then picked the pieces one by one from the container.
The unique number-letter became the subject and group assignment for each individual [2]. The study
was registered in ClinicalTrials.gov NCT02101723. Findings here are from subjects (n = 33 total) who
had fecal samples collected at both time points.
2.2. Subjects
Enrollment of each subject was prior to six months of age. Inclusion criteria: (1) born at term with
birth weight >2500 g; (2) no apparent congenital anomalies; (3) immunization up to date; (4) normal
family social situation such that they were able to comply with study requirements; (5) agree to
weekly visits for MNP distribution and data collection, as well as stool, urine, and blood collections;
(6) hemoglobin (Hb) ≥ 10 g/dL; (7) breastfeeding at enrollment and intent to continue during the
study period; and (8) negative for malaria parasites based on blood smear. Exclusion criteria: (1) acute
malnutrition, with weight for length Z score (Z: number of standard deviations away from the mean)
≤ 2 SD by the World Health Organization (WHO); (2) current or planned use of infant formula or
other nutrient fortified products; (3) current or planned use of iron or zinc supplements; (4) moderate
or severe anemia (Hb < 10 g/dL); (4) previous hospitalization for malaria within the last four weeks;
(5) persistent diarrhea (per WHO, >3 loose stools/day lasting ≥14 days) [2]. There was no use of
antibiotics reported at any time points.
2.3. Micronutrient Powder and Diet
Micronutrient composition of the two intervention MNPs and the placebo are listed in Table 1.
Iron was in the form of ferrous fumarate and was microencapsulated. The placebo was made of
inactive powder. Laboratory analysis at the University of Colorado (UC) verified the accuracy of the
zinc and iron contents of the products. All of the MNP sachets were de-identified by the manufacturer
(Hexagon Nutrition Pvt. Ltd., Mumbai, India) to both the study subjects and the study field staff.
During the intervention, seven MNP sachets were provided at weekly home visits to the mother for
the following week, plus three extra in case of a delay in the next visit. Mothers received instructions
to give one sachet each day and to add the entire contents of the sachet to one meal. Infants’ diets
were directly observed over the course of the trial as part of the zinc absorption study (aim 1 of this
trial). The foods were primarily a maize-based porridge, ugali (maize), and vegetables [2]. During the
weekly home visits, the subjects were followed up by the nurse or clinical officer to check the general
health status, ensure compliance, and answer questions that mothers had [2]. To monitor compliance,
the nurse or clinical officer collected empty sachet packets and those that were not consumed (if any).
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Table 1. Micronutrient contents of the MNP 1 per sachet.
MNP+Fe MNP-Fe Placebo
Iron 12.5 mg 0 0
Zinc 5 mg 5 mg 0
Vitamin A 300 µg 300 µg 0
Vitamin C 30 mg 30 mg 0
Folic acid 160 µg 160 µg 0
1 Multiple micronutrient powder.
2.4. Sample Collections
For the purpose of this analysis, fecal samples were collected at baseline (six months) and the
end of the intervention (nine months). Research personnel from UC trained the local field researchers
in the fecal collection procedures. Each stool sample was collected from cloth diapers fitted with
biodegradable liners, which effectively collected stool, but allowed the passage of urine [9]; two
duplicate stool samples were placed in separate sterile collection tubes (Sarstedt, Newton, MA,
USA) containing RNAlater (ThermoFisher Scientific, Waltham, MA, USA). The field workers assisted
mothers with stool collections, using clinical grade gloves and sterile fecal swabs to avoid microbial
contamination. A study nurse at baseline (six months) and the end of the intervention (nine months)
also collected blood samples using heparin vacutainers and butterfly needles. Blood tubes were
incubated without shaking at room temperature for 45 min before being centrifuged for serum
separation. Both fecal and blood samples were placed on ice at the home visits, and were held in a
−20 ◦C freezer for overnight stay at the local hospital until transport the next day to the −70 ◦C freezer
at Moi University (Eldoret, Kenya), using an ice-packed vaccine carrier. Specimens were shipped on
dry ice to the University of Colorado.
2.5. Anthropometric Measurement
Anthropometric measurements, including weight and length, were measured at baseline
(six months) and the end of the intervention (ninr months) in triplicate by the research staff. Details of
the weight and length measurements were published elsewhere [2].
2.6. Fecal Sample Analysis
2.6.1. 16S Amplicon Library Construction
Microbiome sequencing was conducted at the Microbiome Research Consortium at University
of Colorado Denver. Total community genomic DNA was prepared from ~50 mg of stool using the
UltraClean Fecal DNA Isolation Kit (MO BIO Laboratories, Carlsbad, CA, USA). Bacterial profiles
were determined by broad-range amplification and sequence analysis of 16S rRNA genes following
our previously-described methods [13,14]. In brief, amplicons were generated using primers that
target approximately ~270 base pairs of the V4 variable region of the 16S rRNA gene (primers 534F:
GTGCCAGCMGCCGCGGTAA and 805R: GACTACCAGGGTATCTAAT) [15,16]. Polymerase chain
reaction (PCR) products were normalized using a SequalPrepTM kit (Invitrogen, Carlsbad, CA, USA),
pooled, lyophilized, purified and concentrated using a DNA Clean and Concentrator Kit (Zymo, Irvine,
CA, USA). Pooled amplicons was quantified using Qubit Fluorometer 2.0 (Invitrogen, Carlsbad, CA,
USA). The pool was diluted to 4 nM and denatured with 0.2 N NaOH at room temperature. The
denatured DNA was diluted to 15 pM and spiked with 25% of the PhiX (Illumina, Inc., San Diego, CA,
USA) control DNA prior to loading the sequencer. Illumina paired-end sequencing was performed
on the Illumina Miseq platform (Illumina, Inc., San Diego, CA, USA) with versions v2.4 of the MiSeq
Control Software, using a 500 cycle version 2 reagent kit (Illumina, Inc., San Diego, CA, USA).
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2.6.2. 16S rRNA Sequence Analysis
Illumina MiSeq paired-end reads were aligned to human reference genome hg19 with bowtie2 and
matching sequences discarded [17,18]. As previously described, the remaining non-human paired-end
sequences were sorted by sample via barcodes in the paired reads with a python script [14]. The
sorted paired reads were assembled using phrap [19,20]. Pairs that did not assemble were discarded.
Assembled sequence ends were trimmed over a moving window of five nucleotides until the average
quality met or exceeded 20. Trimmed sequences with more than one ambiguity, or shorter than 350 nt,
were discarded. Potential chimeras identified with Uchime (usearch6.0.203_i86linux32) [21] using the
Schloss [22] Silva reference sequences were removed from subsequent analyses. Assembled sequences
were aligned and classified with SINA (1.3.0-r23838) [23] using the 418,497 bacterial sequences in Silva
115NR99 [24] as reference configured to yield the Silva taxonomy. Operational taxonomic units (OTUs)
were produced by clustering sequences with identical taxonomic assignments. This process generated
12,309,588 sequences for 150 samples (median: 82,064 sequences/sample; minimum sample size: 3619;
maximum sample size: 168,818) exclusive of negative controls which were near zero. The median
Goods coverage score was ≥99% at the rarefaction point of 15,000. The software package Explicet
(v2.10.5, www.explicet.org) [25] was used for data management, display, and analysis (rarefied values
for median Good’s coverage).
2.6.3. Fecal Calprotectin Analysis
A quantitative PCR (QPCR) gene expression assay was used to quantify expression of the
calprotectin gene, a marker used for detection of inflammation in the intestines. Calprotectin
protein levels were not measurable because samples were stored in RNAlater. All reactions were
performed in 96-well plates using the BIORAD CFX96 instrument. PCR reactions contains 10 µL
DyNAmo ColorFlash probe QPCR mastermix (ThermoFisher Scientific, Waltham, MA USA), 7 µL
sterile nuclease-free water (ThermoFisher Scientific, Waltham, MA, USA), 1 µL of the S100A8
primers, and 2 µL of sample template. The following primers were used: Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) Hs.PT.51.22847819.gs and S100A8 Hs.PT.51.19654111.gs.
Internal normalization was performed using the GAPDH housekeeping gene. Fold expression change
of S100A8 relative to GAPDH was calculated using the ∆∆Ct method [26].
2.7. Blood Sample Analysis
Markers of systemic inflammation, including α 1-acid glycoprotein (AGP), C-reactive protein
(CRP), TNF-α, IL-6 and IL-8 were analyzed in serum by R & D Systems Quantikine Enzyme-linked
Immunosorbant Assay (ELISA) in the Pediatric Nutrition Laboratory at University of Colorado Denver.
Iron status of the subjects was also measured and already reported [2].
2.8. Statistical Analysis
Sample size calculations were based on the primary hypothesis that iron supplementation would
increase the abundance of pathogenic bacteria and decrease the abundance of beneficial bacteria over a
three-month intervention. We estimated a sample size of 10–15 per group to detect a 10% difference of
relative abundance of a generic organism between groups, considering a SD of 15% with alpha = 0.05.
This sample size gave a power of 71–89%.
Statistical analyses were performed using SAS (version 9.3; SAS Institute Inc., Cary, NC, USA).
Group means are presented as mean ± SD. Baseline parameters were compared using one-way
Analysis of Variance (ANOVA) and Tukey’s multiple comparisons as the post-hoc analysis when
needed. Gender was included as a covariant in the subsequent analysis and results remained
unaffected. Repeated measures ANOVA were used to evaluate the main effects of time, group, and
their interactions on the dependent variables (i.e., microbiome and inflammation markers). Tukey’s
multiple comparisons test was used to compare values between groups as the post hoc analysis
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(adjusting for multiple groups). A paired t-test was used to compare change over time within each
group. Relative abundance (%) of the microbiome data at the phyla and genus levels were analyzed.
The four most abundant phyla, Actinobacteria, Firmicutes, Bacteroidetes, and Proteobacteria, were
analyzed. At the genus level, three genera of interest Clostidium, Escherichia/Shigella, and Bifidobacterium
were analyzed based on previous research by Jaeggi et al., [11] of a comparable design. Multiple
comparisons were adjusted based on the number of models tested (three microbiome strains and seven
inflammation markers). Thus, an adjusted p-value of less than 0.005 is considered significant after
Bonferroni correction (0.05/10 tests = 0.005). p-values between 0.005 and 0.05 were also reported and
considered nominally significant.
3. Results
3.1. Subject Characteristics
A subgroup of 33 subjects who completed the fecal sample collections at both time points were
included in this analysis: MNP+Fe: n = 13; MNP-Fe: n = 13; CONTROL: n = 7. The discrepancy of
sample sizes between groups did not appear to be related to the intervention: (1) the intervention
was double-blind; (2) some stool samples were missing labels during shipment or the quantity was
not adequate. Subjects’ demographics and anthropometric data are summarized in Table 2. In brief,
there were no differences in demographic or anthropometric measurements between groups. Both
weight and length increased over time as expected among all subjects (data not shown) with no group
differences. No cases of malaria were identified in the subjects during the study period. Compliance
monitoring for the assigned MNP indicated > 90% consumption among the participants [2].
Table 2. Demographics and anthropometrics at six months of age 1.
MNP+Fe (n = 15) MNP−Fe (n = 15) Control (n = 15)
Male 5 (33%) 7 (47%) 10 (67%)
Female 10 (67%) 8 (53%) 5 (33%)
Weight, kg 7.25 ± 0.25 7.55 ± 0.27 7.49 ± 0.22
WAZ 2 −0.39 ± 0.25 −0.16 ± 0.31 −0.21 ± 0.25
Length, cm 65.0 ± 0.7 66.5 ± 0.9 64.6 ± 0.8
LAZ 2 −0.68 ± 0.27 −0.19 ± 0.40 −1.01 ± 0.39
1 Mean ± SEM; no difference between groups of any parameter; 2 WAZ: weight-for-age Z score; LAZ: length-for-age
Z score.
There was no difference between groups for hemoglobin, ferritin, soluble transferrin receptor,
plasma zinc, or exchangeable zinc poo (EZP) at baseline. After the intervention, plasma zinc
concentration decreased without differences between groups. Serum ferritin did not change over time
or between groups, but soluble transferrin receptor demonstrated a significant increase, with trend for
greater increase in the control group [2].
3.2. Microbiome Changes over Time
The Good’s index of each sequence library at six and nine months for the three groups were all
higher than 99%, indicating that most biodiversity was captured in each library (subject), and that the
depth of sequencing was sufficient to represent the biodiversity in the specimens. Ecological indices of
richness (Schao1) increased overtime from 6–9 months (p < 0.0001) but no between-group differences
were noted. The increase of diversity corresponded to the subjects’ increase in food variety. These
numbers are within the similar range we previously reported in breastfed infants in Denver, CO,
USA [9].
The four most abundant phyla at baseline were Actinobacteria (20 ± 13% relative abundance
[RA]), Bacteroidetes (17 ± 19% RA), Firmicutes (24 ± 13% RA), and Proteobacteria (38 ± 21% RA),
wherease the rest of the phyla accounted for less than 1% of 16S rRNA sequences. There was no
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significant effect of group (p = 0.1) at the phylum level but a nominal significant effect of time for
Actinobacteria (p = 0.02), Bacteroidetes (p = 0.009) and Proteobacteria (p = 0.008). Figure 1 showed
the breakdown of the relative abundance change overtime within each group. When consuming
their regular diet plus a placebo MNP over there months (CONTROL), the relative abundance of
Bacteroidetes (p = 0.04) increased and Proteobacteria (p = 0.02) decreased. There was also a borderline
decrease of Actinobacteria in CONTROL (p = 0.07). The abundance of Actinobacteria also was
decreased in MNP+Fe (p = 0.02).
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Figure 1. The change of relative abundance at the phyla level.
At the genus level at baseline, Escherichia/Shigella, (30.1 ± 23%) and Bifidobacterium (17.3 ± 11.1%)
were the first and second most abundant genera among all groups, while Clostridium (1.4 ± 3.5%) was
the eighth most abundant genus. As shown in Figure 2, the relative abundance of Escherichia/Shigella
significantly decreased over time in the MNP-Fe (−16.05 ± 6.9%, p = 0.05) and CONTROL
(−19.75 ± 4.5%, p = 0.01) groups, but not in the MNP+Fe group (−6.0 ± 9%, p = 0.41). The
relative abundance of Bifidobacterium decreased in MNP+Fe (−6.38 ± 2.5%, p = 0.02) and CONTROL
(−8.05 ± 1.46%, p = 0.01), but not in the MNP-Fe group (−4.3 ± 5%, p = 0.44). In addition, Clostridium
increased abundance in MNP-Fe only (1.94 ± 2%, p = 0.007). No significant difference was found for
the ratios of Escherichia/Shigella to Bifidobacterium or Escherichia/Shigella to Clostridium between groups
(log of the abundance).
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3.3. Inflammation Markers
AGP and CRP concentrations were previously reported [2]. Table 3 summarizes the serum
inflammatory markers AGP, CRP, TNF-α, IL-6, IL-8, and fecal calprotectin at six and nine months of
age. Briefly, none of the inflammation markers changed over time or between groups, except for IL-8,
which decreased in CONTROL (group-by-time interaction p = 0.02). CRP was above the upper limit of
the normal range for all groups at both time points.
Table 3. Mean (± SEM) inflammation markers at six and nine months of age 1.
Biomarkers (Normal Range)
MNP+Fe MNP-Fe Control
Six Months NineMonths Six Months
Nine
Months Six Months
Nine
Months
AGP (mg/dL) (50–120) 87 ± 14 (10) 91 ± 19 (10) 81 ± 17 (7) 81 ± 12 (7) 82 ± 15 (9) 80 ± 13 (9)
CRP (mg/L) (<3) 7.7 ± 4.5 (10) 6.2 ± 3.4 (10) 11.5 ± 5.9 (8) 8.3 ± 4.2 (8) 5.3 ± 1.8 (8) 6.2 ± 1.7 (9)
IL-6 (pg/mL) (<39) 7.5 ± 4.0 (12) 5.1 ± 2.4 (15) 8.8 ± 3.0 (14) 3.2 ± 0.9 (14) 5.8 ± 2.4 (10) 5.0 ± 1.6 (11)
IL-8 (pg/mL) 2 (<81.8) 39 ± 11 (12) 30 ± 4 (14) 40 ± 20 (14) 32 ± 8 (14) 51 ± 13 (10) 22 ± 3 (11)
TNF-α (pg/mL) (<3.3) 8.7 ± 1.1 (14) 8.6 ± 0.8 (15) 12.2 ± 3.0 (14) 8.3 ± 1.0 (15) 9.1 ± 1.3 (10) 7.3 ± 1.1 (11)
Fecal calprotectin (fold change) 1.6 ± 0.6 (10) 2.1 ± 0.6 (11) 3.4 ± 0.8 (12) 2.5 ± 0.8 (8) 4.3 ± 1.4 (6) 2.3 ± 1.1 (6)
1 Mean ± SEM (n); 2 Decreased in CONTROL (group-by-time interaction p = 0.02).
4. Discussion
This study showed that in 6–9 month old breastfed African infants who were generally not anemic,
home fortification with iron containing MNP could alter the gut microbiome in favor of potential
pathogens, compared with infants who received MNP without iron or no MNP at all. Jaeggi et al. [11]
conducted a double-blind, randomized, controlled trial in Kenyan infants of comparable design as
our study, but with a larger sample size. In Jaeggi et al.’s study [11], six-month old Kenyan infants,
who had high rates of IDA (64%), were randomized to receive MNP with iron (12.5 or 2.5 mg/day)
or MNP with no iron for four months. Their results indicated that iron supplementation increased
Escherichia/Shigella and Clostridium accompanied by elevated intestinal inflammation status [11]. The
12.5 mg Fe/day MNP used had a similar composition with our study, except for lower folic acid.
However, limited research has shown that folic acid had minimum impact on the gut microbiome [27].
The 2.5 mg Fe/day MNP in Jaeggi et al.’s study [11] also contained 11 other micronutrient and resulted
in a slightly different impact on the microbiome, especially for Escherichia/Shigella. This differential
impact could be due to the different quantity of iron or the other micronutrients in the 2.5 mg Fe/day
MNP, but this cannot be distinguished by the design of the study [11]. Another study [10] by the same
group showed that in older African children, 20 mg/day iron fortification resulted in a significant
increase in the abundance of enterobacteria, a decrease in lactobacilli, and a significant increase in
fecal calprotectin. Findings from a complementary feeding intervention of older infants, with a
larger sample size and longer intervention, suggested that iron-fortified cereal was associated with
higher systemic inflammation and impaired linear growth; the effect on the gut microbiota was not
reported [28]. These studies, although differing from our study by the environment, iron dosage, and
subjects’ age, all demonstrated the potential pathogen-promoting nature of elevated iron in the human
gut in low-resource settings.
The four predominant phyla observed in this study were comparable to previous studies
conducted by our group [9,29] and others [30]. However, we found a higher abundance of
Proteobacteria at 38% compared with other studies [11,30] that reported typical abundances less than
10%. Although comparing the results of microbiome studies can be challenging due to methodological
differences, these results suggest the possibility that these Kenyan infants at six months of age
were colonized by a potentially more pathogenic microbiome than observed in other environments.
In addition to the environment, diet also plays an important role in modulating the microbiome. For
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instance, children from Europe and rural Africa have been reported to display distinctly different
microbial communities [30]. The most profound difference was observed in Bacteroidetes, specifically
the genus Prevotella, which is known for polysaccharide hydrolysis. This finding is consistent with
the fiber-rich diet characteristic of many rural African children, compared with children from Europe.
In our study, the relative abundance of Bacteroidetes also increased over time, concurrently with the
increase of complementary feeding and food variety, particularly the intake of maize-based foods.
The three genera Bifidobacterium, Escherichia/Shigella, and Clostridium were chosen for analysis
based on previous research by Jaeggi et al. [11] of a comparable design. The genus Bifidobacterium is
usually predominant in breastfed infants and is one of the beneficial “barrier” strains that prevent
pathogen colonization and adhesion to epithelial cells of the host [31]. The abundance of Bifidobacterium
usually declines with age. In our study, the abundance of Bifidobacterium at six months was 17.3% on
average, which was much lower than what Jaeggi et al. [11] reported at 63%. This discrepancy could be
due to the 16S rRNA gene primer bias [32], although the primers used in this study were designed to
minimize the bias in amplifying bifidobacteria [33]. Moreover, our findings are in the range of previous
research [30,34], including our own studies [9,35]. In our study, Bifidobacterium decreased over time
in both MNP+Fe and CONTROL, but not MNP-Fe. The decrease in CONTROL is expected because
Bifidobacterium usually decreases its abundance with age [31]. Moreover, the decrease in MNP+Fe was
consistent with previous research by Jaeggi et al. [11] that also showed a decrease in Bifidobacterium
abundance from 6–10 months of age with the same daily iron supplementation. However, the study by
Jaeggi et al. [11] did not include a control group to reflect the natural change of microbial colonization
with time. Thus, at least for Bifidobacterium, our study suggests that inclusion of 12.5 mg of iron in MNP
did not have additive negative effects to the host. Nonetheless, in the MNP-Fe group, Bifidobacterium
did not significantly decrease over time, suggesting the potential beneficial effect of MNP without iron,
on attenuating the natural decline of Bifidobacterium in these infants. Our results also indicated that the
genus Escherichia/Shigella decreased in abundance in MNP-Fe and CONTROL, but not MNP+Fe. This
is an interesting finding because, unlike the study by Jaeggi et al. [11], iron supplementation in our
study did not promote the growth of Escherichia/Shigella per se, but rather prevented its decrease over
time, as observed in MNP-Fe and CONTROL. Furthermore, the abundance of the genus Clostridium
did not change in MNP+Fe and CONTROL, but only MNP-Fe. Overall, our findings suggest that
at the genus level, standard iron supplementation (12.5 mg/day) in the form of MNP affected the
gut microbiome in a potentially adverse fashion by inhibiting the natural diminution over infancy of
Escherichia/Shigella. Meanwhile, MNP without iron had mixed effects on the microbiome by inhibiting
the decrease of Bifidobacterium while promoting the growth of Clostridium. Without sub-phyla level
determinations, it is impossible to predict the likely impact of the latter. In our earlier study in Denver,
high iron intake was associated with lower Clostridium group XIVa, which includes clostridial species
that are butyrate-producing and immunomodulatory [9].
Although our study found that iron supplementation decreased potentially beneficial strains
(e.g., Bifidobacterium spp.) and attenuated the temporal decrease of pathogenic strains (e.g.,
Escherichia spp.), no statistically significant effect on inflammation status was found. In CONTROL,
IL-8 did decrease over time, but MNP+Fe and MNP-Fe did not significantly increase any
inflammation markers, including fecal calprotectin, which previous studies found increased with
iron supplementation [10,11]. This lack of a significant change could be due, at least partially, to a
relatively small sample size. Additionally, these infants already had a high burden of inflammation at
baseline, which may diminish the intervention effect. Moreover, due to the nature of sample storage,
fecal calprotectin in this study was measured as gene expression, which did not necessarily reflect
protein levels. However, unlike previous studies [10,11], we did not find an increase of the pathogenic
strains (Escherichia/Shigella, Clostridium) with iron supplementation, which may also contribute to the
unchanged inflammation status in these infants.
Strengths of our study include targeting non-anemic infants in rural Kenya, a group that may not
need iron supplementation and are thus more susceptible to adverse effects of iron supplementation,
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especially in the setting of a high inflammatory burden and endemic malaria [3]. In addition, we
included a control group to demonstrate the natural change of the gut microbiome in these infants.
There are also a number of limitations of this trial. First, our sample size was much smaller compared
with that of Jaeggi et al. [11]. Our study was initiated in 2011 and power and sample size were
calculated based on very limited research available at that time. Data that demonstrate substantial
variability have emerged since and our study appears to be underpowered. Nonetheless, our findings
contribute to this important research topic because of our targeted population and inclusion of a
control group. Another limitation, common to other studies, was the lack of long-term follow up.
Although the relative abundance of some potential pathogens remained with iron supplementation, it
is not clear how this would affect the health status of the host in the long term, for example, in relation
to growth [28]. Lastly, some of infants (in all groups) had already started complementary foods at
baseline, but the foods were likely to have been virtually the same as those consumed during the
intervention period. By reporting the change over time within participants, we could partially control
the individual variances of the gut microbiome.
Iron deficiency is the most prevalent micronutrient deficiency in the world and finding an
adequate and safe dosage of iron to rectify this deficiency has tremendous public health impact [36–38].
Ours was the first randomized, controlled trial that examined the effect of standard and widely-used
iron supplementation on the gut microbiome in non- or mildly-anemic African infants. The quantity
of iron provided in this study was 12.5 mg/day, which is the standard quantity in commonly-used
MNP “sprinkles”. This dosage has been shown to be effective in terms of reducing ID and IDA
in older African infants and toddlers. Lower iron doses have also been tested, with the aim of
reducing its negative health impacts (e.g., inflammation, diarrhea). For example, MNP with a much
lower iron content (2.5 mg/day) was tested in several trials in African children, but results were
not promising [39,40]. Additionally, Jaeggi et al. [11] found it unclear whether 2.5 mg/day of iron,
compared with 12.5 mg/day, had a better safety profile. Future preventive iron interventions could
consider the impact of lower doses, effects of absorption enhancers, such as vitamin C, and/or
anti-inflammatory agents, such as Vitamin E [29], to the MNP. Ultimately, additional research needs
to be done to determine the most effective dosage with minimum side effects to both infant health
and to the developing microbiota. Moreover, longer term studies will be required to link the effects of
alterations in the microbiota with clinically-relevant outcomes.
Acknowledgments: This research was funded by International Atomic Energy Agency (IAEA) research contract
No. 15827 and technical contract no. 16933; National Institutes of Health/National Center for Research Resources
(NIH/NCRR) Colorado Clinical and Translational Sciences Institute (CCTSI) Grant Number UL1 TR001082.
Supplemental grant support for Nancy F. Krebs was provided by NIH K24 DK083772. The funding sponsors
had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the
manuscript, and in the decision to publish the results, however IAEA had limited collaborative input into the
refinement of the protocol before implementation in the field.
Author Contributions: N.F.K., F.E., K.M.H. and E.L. designed and conducted the study and reviewed the paper.
M.T. and N.F.K. wrote the paper. D.N.F., A.E.H. and D.I. analyzed data and reviewed the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Pasricha, S.R.; Drakesmith, H.; Black, J.; Hipgrave, D.; Biggs, B.A. Control of iron deficiency anemia in low-
and middle-income countries. Blood 2013, 121, 2607–2617. [CrossRef] [PubMed]
2. Esamai, F.; Liechty, E.; Ikemeri, J.; Westcott, J.; Kemp, J.; Culbertson, D.; Miller, L.V.; Hambidge, K.M.;
Krebs, N.F. Zinc absorption from micronutrient powder is low but is not affected by iron in Kenyan infants.
Nutrients 2014, 6, 5636–5651. [CrossRef] [PubMed]
3. Sazawal, S.; Black, R.E.; Ramsan, M.; Chwaya, H.M.; Stoltzfus, R.J.; Dutta, A.; Dhingra, U.; Kabole, I.; Deb, S.;
Othman, M.K.; et al. Effects of routine prophylactic supplementation with iron and folic acid on admission
to hospital and mortality in preschool children in a high malaria transmission setting: Community-based,
randomised, placebo-controlled trial. Lancet 2006, 367, 133–143. [CrossRef]
Nutrients 2017, 9, 776 11 of 12
4. Soofi, S.; Cousens, S.; Iqbal, S.P.; Akhund, T.; Khan, J.; Ahmed, I.; Zaidi, A.K.; Bhutta, Z.A. Effect of provision
of daily zinc and iron with several micronutrients on growth and morbidity among young children in
Pakistan: A cluster-randomised trial. Lancet 2013, 382, 29–40. [CrossRef]
5. Paganini, D.; Uyoga, M.A.; Zimmermann, M.B. Iron Fortification of Foods for Infants and Children in
Low-Income Countries: Effects on the Gut Microbiome, Gut Inflammation, and Diarrhea. Nutrients 2016, 8.
[CrossRef] [PubMed]
6. Andrews, S.C.; Robinson, A.K.; Rodriguez-Quinones, F. Bacterial iron homeostasis. FEMS Microbiol. Rev.
2003, 27, 215–237. [CrossRef]
7. Mevissen-Verhage, E.A.; Marcelis, J.H.; Harmsen-Van Amerongen, W.C.; de Vos, N.M.; Verhoef, J. Effect
of iron on neonatal gut flora during the first three months of life. Eur. J. Clin. Microbiol. 1985, 4, 273–278.
[CrossRef] [PubMed]
8. Vazquez-Gutierrez, P.; de Wouters, T.; Werder, J.; Chassard, C.; Lacroix, C. High Iron-Sequestrating
Bifidobacteria Inhibit Enteropathogen Growth and Adhesion to Intestinal Epithelial Cells In Vitro.
Front. Microbiol. 2016, 7, 1480. [CrossRef] [PubMed]
9. Krebs, N.F.; Sherlock, L.G.; Westcott, J.; Culbertson, D.; Hambidge, K.M.; Feazel, L.M.; Robertson, C.E.;
Frank, D.N. Effects of different complementary feeding regimens on iron status and enteric microbiota in
breastfed infants. J. Pediatr. 2013, 163, 416–423. [CrossRef] [PubMed]
10. Zimmermann, M.B.; Chassard, C.; Rohner, F.; N’Goran, E.K.; Nindjin, C.; Dostal, A.; Utzinger, J.; Ghattas, H.;
Lacroix, C.; Hurrell, R.F. The effects of iron fortification on the gut microbiota in African children:
A randomized controlled trial in Cote d’Ivoire. Am. J. Clin. Nutr. 2010, 92, 1406–1415. [CrossRef] [PubMed]
11. Jaeggi, T.; Kortman, G.A.; Moretti, D.; Chassard, C.; Holding, P.; Dostal, A.; Boekhorst, J.; Timmerman, H.M.;
Swinkels, D.W.; Tjalsma, H.; et al. Iron fortification adversely affects the gut microbiome, increases pathogen
abundance and induces intestinal inflammation in Kenyan infants. Gut 2015, 64, 731–742. [CrossRef]
[PubMed]
12. Goudar, S.S.; Carlo, W.A.; McClure, E.M.; Pasha, O.; Patel, A.; Esamai, F.; Chomba, E.; Garces, A.; Althabe, F.;
Kodkany, B.; et al. The Maternal and Newborn Health Registry Study of the Global Network for Women’s
and Children’s Health Research. Int. J. Gynaecol. Obstet. 2012, 118, 190–193. [CrossRef] [PubMed]
13. Hara, N.; Alkanani, A.K.; Ir, D.; Robertson, C.E.; Wagner, B.D.; Frank, D.N.; Zipris, D. Prevention of
Virus-Induced Type 1 Diabetes with Antibiotic Therapy. J. Immunol. 2012, 189, 3805–3814. [CrossRef]
[PubMed]
14. Markle, J.G.; Frank, D.N.; Mortin-Toth, S.; Robertson, C.E.; Feazel, L.M.; Rolle-Kampczyk, U.; von Bergen, M.;
McCoy, K.D.; Macpherson, A.J.; Danska, J.S. Sex differences in the gut microbiome drive hormone-dependent
regulation of autoimmunity. Science 2013, 339, 1084–1088. [CrossRef] [PubMed]
15. Lane, D.J.; Pace, B.; Olsen, G.J.; Stahl, D.A.; Sogin, M.L.; Pace, N.R. Rapid determination of 16S ribosomal
RNA sequences for phylogenetic analyses. Proc. Natl. Acad. Sci. USA 1985, 82, 6955–6959. [CrossRef]
[PubMed]
16. Weisburg, W.G.; Barns, S.M.; Pelletier, D.A.; Lane, D.J. 16S ribosomal, DNA amplification for phylogenetic
study. J. Bacteriol. 1991, 173, 697–703. [CrossRef] [PubMed]
17. Homo Sapiens UCSC Hg19 Human Genome Sequence from iGenome: Illumina. 2009. Available online: http:
//support.illumina.com/sequencing/sequencing_software/igenome.ilmn (accessed on 14 August 2014).
18. Langmead, B.; Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 2012, 9, 357–359.
[CrossRef] [PubMed]
19. Ewing, B.; Green, P. Base-calling of automated sequencer traces using phred. II. Error probabilities.
Genome Res. 1998, 8, 186–194. [CrossRef] [PubMed]
20. Ewing, B.; Hillier, L.; Wendl, M.C.; Green, P. Base-calling of automated sequencer traces using phred. I.
Accuracy assessment. Genome Res. 1998, 8, 175–185. [CrossRef] [PubMed]
21. Edgar, R.C.; Haas, B.J.; Clemente, J.C.; Quince, C.; Knight, R. UCHIME improves sensitivity and speed of
chimera detection. Bioinformatics 2011, 27, 2194–2200. [CrossRef] [PubMed]
22. Schloss, P.D.; Westcott, S.L. Assessing and improving methods used in operational taxonomic unit-based
approaches for 16S rRNA gene sequence analysis. Appl. Environ. Microbiol. 2011, 77, 3219–3226. [CrossRef]
[PubMed]
23. Pruesse, E.; Peplies, J.; Glockner, F.O. SINA: Accurate high throughput multiple sequence alignment of
ribosomal RNA genes. Bioinformatics 2012, 28, 1823–1829. [CrossRef] [PubMed]
Nutrients 2017, 9, 776 12 of 12
24. Quast, C.; Pruesse, E.; Yilmaz, P.; Gerken, J.; Schweer, T.; Yarza, P.; Peplies, J.; Glockner, F.O. The SILVA
ribosomal RNA gene database project: Improved data processing and web-based tools. Nucleic Acids Res.
2013, 41, D590–D596. [CrossRef] [PubMed]
25. Robertson, C.E.; Harris, J.K.; Wagner, B.D.; Granger, D.; Browne, K.; Tatem, B.; Feazel, L.M.; Park, K.;
Pace, N.R.; Frank, D.N. Explicet: Graphical user interface software for metadata-driven management,
analysis and visualization of microbiome data. Bioinformatics 2013, 29, 3100–3101. [CrossRef] [PubMed]
26. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–408. [CrossRef] [PubMed]
27. MacFarlane, A.J.; Behan, N.A.; Matias, F.M.; Green, J.; Caldwell, D.; Brooks, S.P. Dietary folate does not
significantly affect the intestinal microbiome, inflammation or tumorigenesis in azoxymethane-dextran
sodium sulphate-treated mice. Br. J. Nutr. 2013, 109, 630–638. [CrossRef] [PubMed]
28. Ma, J.; Sun, Q.; Liu, J.; Hu, Y.; Liu, S.; Zhang, J.; Sheng, X.; Hambidge, K.M. The Effect of Iron Fortification on
Iron (Fe) Status and Inflammation: A Randomized Controlled Trial. PLoS ONE 2016, 11, e0167458. [CrossRef]
[PubMed]
29. Tang, M.; Frank, D.N.; Sherlock, L.; Ir, D.; Robertson, C.E.; Krebs, N.F. Effect of Vitamin E with Therapeutic
Iron Supplementation on Iron Repletion and Gut Microbiome in US Iron Deficient Infants and Toddlers.
J. Pediatr. Gastroenterol. Nutr. 2016, 63, 379–385. [CrossRef] [PubMed]
30. De Filippo, C.; Cavalieri, D.; Di Paola, M.; Ramazzotti, M.; Poullet, J.B.; Massart, S.; Collini, S.; Pieraccini, G.;
Lionetti, P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe
and rural Africa. Proc. Natl. Acad. Sci. USA 2010, 107, 14691–14696. [CrossRef] [PubMed]
31. Ottman, N.; Smidt, H.; de Vos, W.M.; Belzer, C. The function of our microbiota: Who is out there and what
do they do? Front. Cell. Infect. Microbiol. 2012, 2, 104. [CrossRef] [PubMed]
32. Koenig, J.E.; Spor, A.; Scalfone, N.; Fricker, A.D.; Stombaugh, J.; Knight, R.; Angenent, L.T.; Ley, R.E.
Succession of microbial consortia in the developing infant gut microbiome. Proc. Natl. Acad. Sci. USA 2011,
108 (Suppl. S1), 4578–4585. [CrossRef] [PubMed]
33. Frank, J.A.; Reich, C.I.; Sharma, S.; Weisbaum, J.S.; Wilson, B.A.; Olsen, G.J. Critical evaluation of two primers
commonly used for amplification of bacterial 16S rRNA genes. Appl. Environ. Microbiol. 2008, 74, 2461–2470.
[CrossRef] [PubMed]
34. Fallani, M.; Amarri, S.; Uusijarvi, A.; Adam, R.; Khanna, S.; Aguilera, M.; Gil, A.; Vieites, J.M.; Norin, E.;
Young, D.; et al. Determinants of the human infant intestinal microbiota after the introduction of first
complementary foods in infant samples from five European centres. Microbiology 2011, 157 Pt 5, 1385–1392.
[CrossRef] [PubMed]
35. Brumbaugh, D.E.; Crume, T.L.; Nadeau, K.; Scherzinger, A.; Dabelea, D. Intramyocellular lipid is associated
with visceral adiposity, markers of insulin resistance, and cardiovascular risk in prepubertal children: The
EPOCH study. J. Clin. Endocrinol. Metab. 2012, 97, E1099–E1105. [CrossRef] [PubMed]
36. American Academy of Pediatrics CoN. Iron. In Pediatric Nutrition Handbook, 6th ed.; Kleinman, R., Ed.;
American Academy of Pediatrics: Elk Grove Village, IL, USA, 2009; pp. 403–422.
37. Lutter, C.K. Iron deficiency in young children in low-income countries and new approaches for its prevention.
J. Nutr. 2008, 138, 2523–2528. [CrossRef] [PubMed]
38. Baker, R.D.; Greer, F.R. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants
and young children (0–3 years of age). Pediatrics 2010, 126, 1040–1050. [CrossRef] [PubMed]
39. Troesch, B.; van Stuijvenberg, M.E.; Smuts, C.M.; Kruger, H.S.; Biebinger, R.; Hurrell, R.F.; Baumgartner, J.;
Zimmermann, M.B. A micronutrient powder with low doses of highly absorbable iron and zinc reduces
iron and zinc deficiency and improves weight-for-age Z-scores in South African children. J. Nutr. 2011, 141,
237–242. [CrossRef] [PubMed]
40. Macharia-Mutie, C.W.; Moretti, D.; Van den Briel, N.; Omusundi, A.M.; Mwangi, A.M.; Kok, F.J.;
Zimmermann, M.B.; Brouwer, I.D. Maize porridge enriched with a micronutrient powder containing
low-dose iron as NaFeEDTA but not amaranth grain flour reduces anemia and iron deficiency in Kenyan
preschool children. J. Nutr. 2012, 142, 1756–1763. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
